EUVIMEDEUVIMED entdecken
Crossref

Membrane-confined self-assembly enables localized bioorthogonal prodrug activation and selective cancer therapy

Wenjie Wang, Jiaxin Guo, Hong Han, Dan Yuan, Junfeng Shi

Science Advances · 20.11.2026 · 12 (47)

DOI: 10.1126/sciadv.aeg8356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 20.11.2026. Verfasst von Wenjie Wang und 4 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Hunan Province, Natural Science Foundation of Guangdong.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bioorthogonal prodrug activation offers a promising approach for site-specific drug release, significantly reducing the systemic toxicity associated with conventional chemotherapy. However, challenges remain in precisely controlling prodrug activation at the target site while maintaining optimal selectivity, reactivity, and potency. Here, we report a dual-targeting peptide, TzFFY p HH, that integrates on-membrane enzyme-instructed self-assembly (EISA) with bioorthogonal chemistry to enable selective chemotherapy. Exploiting the overexpression of alkaline phosphatase (ALP) and programmed death-ligand 1 (PD-L1) on cancer cells, TzFFY p HH selectively anchors and self-assembles on the cancer cell membrane, enriching tetrazine (Tz) handles that act as bioorthogonal reactors to activate a trans -cyclooctene (TCO)-caged prodrug (TCO-Dox) for precise drug release. Upon topical administration, TzFFY p HH forms a hydrogel at subcutaneous tumor sites, enabling in situ prodrug activation for effective tumor inhibition. Notably, this localized chemotherapy elicits a potent antitumor immune response, which, when combined with anti-programmed death-1 antibody (αPD-1), synergistically potentiates therapeutic outcomes. By coupling supramolecular self-assembly with bioorthogonal reactivity on the cell membrane, this work establishes a chemically programmable platform for spatiotemporally controlled prodrug activation and provides a general strategy for integrating localized chemotherapy with immunotherapy.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Program of Hunan Province
  • Natural Science Foundation of Guangdong
  • Natural Science Foundation of Hunan
  • Science and Technology and Development Foundation of Shenzhen

Zitieren

APA

Wang, W., Guo, J., Han, H., Yuan, D., & Shi, J. (2026). Membrane-confined self-assembly enables localized bioorthogonal prodrug activation and selective cancer therapy. Science Advances, 12(47). https://doi.org/10.1126/sciadv.aeg8356

Vancouver

Wang W, Guo J, Han H, Yuan D, Shi J. Membrane-confined self-assembly enables localized bioorthogonal prodrug activation and selective cancer therapy. Science Advances. 2026;12(47). doi:10.1126/sciadv.aeg8356

BibTeX
@article{Wang2026,
  author = {Wang, Wenjie and Guo, Jiaxin and Han, Hong and Yuan, Dan and Shi, Junfeng},
  title = {Membrane-confined self-assembly enables localized bioorthogonal prodrug activation and selective cancer therapy},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {47},
  doi = {10.1126/sciadv.aeg8356}
}
Kostenlos starten →